ST Pharm Co.,Ltd. (KOSDAQ:237690)

Market Cap	1.68T
Revenue (ttm)	274.45B
Net Income (ttm)	29.52B
Shares Out	20.15M
EPS (ttm)	1,488.44
PE Ratio	55.96
Forward PE	41.01
Dividend	500.00 (0.58%)
Ex-Dividend Date	Dec 27, 2024

Volume	106,580
Average Volume	111,260
Open	86,500
Previous Close	85,600
Day's Range	83,200 - 86,700
52-Week Range	66,600 - 120,800
Beta	0.73
RSI	57.51
Earnings Date	Jul 25, 2025

About ST Pharm

ST Pharm Co.,Ltd., provides custom manufacturing services for active pharmaceutical ingredient and intermediates in South Korea and internationally. The company offers small molecule and generics, an ingredient for treating viral infections; oligonucleotide based products, such as siRNA/microRNA, antisense, aptamer, decoys, and other novel oligos; monomer; and mRNA for vaccines and therapeutics. It also offers pre-clinical and bioanalytical R and D solutions. The company was formerly known as Samchully Pharmaceutical Company., Ltd. ST Pharm Co....

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1983
• Employees: 655
• Stock Exchange: KOSDAQ
• Ticker Symbol: 237690

Financial Performance

In 2024, ST Pharm's revenue was 273.75 billion, a decrease of -3.94% compared to the previous year's 284.99 billion. Earnings were 34.71 billion, an increase of 77.27%.